Bristol Myers Squibb just became the first pharma company to buy Nvidia's brand-new Vera Rubin supercomputer — and the goal is simple: test dozens more experimental drugs, faster, before they ever reach a human trial.
Let that sink in.
We're not talking about a chatbot upgrade.
We're talking about the machine that decides which molecules get a shot at becoming medicine.
Robert Plenge, BMS's chief research officer, put it bluntly:
"Maybe before we could do 10 and now we can do dozens."
That's not a small efficiency bump.
That's the entire drug-discovery funnel widening overnight.
That last one matters more than it sounds.
Greg Meyers, BMS's chief digital and technology officer, said it plainly:
"Electricity is not getting cheaper."
Running massive AI models isn't just a compute problem anymore.
It's a power-grid problem.
This upgrade — two or three generations ahead of BMS's previous system — is as much about efficiency as it is about raw horsepower.
Pharma has always been slow, expensive, and brutal on odds — most drugs fail long before they ever reach a pharmacy shelf.
AI doesn't remove that risk.
But it lets companies fail faster, cheaper, and earlier — before spending years and billions on a dead end.
BMS just bet, first and biggest, that owning the fastest AI engine in life sciences is worth more than owning the next blockbuster drug alone.
Because in this race, speed to failure might be the real superpower.
That's all for now!
